The Affordability Resilience Dilemma: What Generic Drug Tariffs Could Mean for Competition, Access, and Cost

The proposed tariff on imported generic medicines is often framed as a manufacturing or trade policy story. That framing is understandable, but incomplete. Generics are not a peripheral part of U.S. prescription drug component of healthcare; they are the affordability backbone of the system. In 2024, generics represented approximately 90% of all prescriptions filled in the U.S., while accounting for only 12% of prescription drug spending. If policy changes alter the economics of generic supply, the consequences may be felt not only by manufacturers, but also by all parties involved in the prescription drug component of the healthcare ecosystem: payers, both public (Medicare and Medicaid) and private, as well as channel trade partners such as wholesalers, retailers, hospitals, long term care providers, physicians, and ultimately patients.^1-2

In July 2026, President Donald Trump announced a phased proposal under which imported generic medicines would remain tariff-free for two years, through July 31, 2028, before becoming subject to a 100% tariff from August 1, 2028, through July 31, 2029, and a 200% tariff thereafter beginning August 1, 2029. The stated objective is to encourage domestic pharmaceutical manufacturing and reduce dependence on foreign supply chains. That objective speaks to a legitimate policy concern: the U.S. healthcare system relies heavily on globally distributed pharmaceutical production.^3-5

However, for market access stakeholders, the critical question is not simply whether tariffs can encourage reshoring. The more important question is whether the U.S. can strengthen supply-chain resilience without weakening the competitive and drug pricing dynamics that made generics affordable in the first place. In other words, the tariff debate is not only about where medicines are made. It is also about who can afford to manufacture them, who can recover higher costs, who remains competitive, and who ultimately pays, if affordability is disrupted.

Generic medicines have long been one of the most important drivers of affordability in the U.S. pharmaceutical market. By introducing competition after patent expiry, generics allow the entire healthcare ecosystem to access therapeutically equivalent medicines at substantially lower prices than their branded counterparts. From cheaper medicines to less expensive patient copays, generics are the first line of therapy in many disease states.

The scale of generic utilization illustrates why any policy affecting the sector carries system-wide implications. According to the FDA, Association for Accessible Medicines (AAM) report and other sources, more than 90% of medicines sold in the United States are generic products, and nearly 9 out of every 10 prescriptions filled are for generics. AAM estimates that generic medicines and biosimilars generated approximately $467 billion in healthcare savings in 2024 and approximately $3.4 trillion over the past decade.^1-4

This creates a policy paradox. Generics account for the overwhelming majority of prescription volume but a relatively small share of prescription drug spending. That is precisely why they matter so much and are excluded from many policy initiatives such as Medicare drug price negotiations under the Inflation Reduction Act (IRA) or Most Favored Nation (MFN). Even small changes in the economics of generic supply can reverberate broadly across public programs, commercial plans, hospital procurement, pharmacy economics, and patient affordability.²

The affordability of generic medicines has been supported by a global manufacturing model built around cost efficiency, scale, specialized production capabilities, and dispersed supply networks. Over several decades, production of active pharmaceutical ingredients, intermediates, and finished-dose products shifted across international markets, helping lower production costs and support broad generic availability. A main rationale of why generic drugs are cheap is because they are manufactured at scale overseas with a cost structure much different than a US based cost structure. In addition, generic manufacturers have not built factories in the United States as they have for branded products because they operate on razor-thin margins.

This generic model has delivered economic benefits, but it has also created exposure to supply-chain concentration and geopolitical risk. A substantial share of pharmaceuticals distributed in the United States are manufactured outside the country, with a particularly high reliance on overseas API manufacturing. Only a minority of API manufacturing sites serving the U.S. market are located domestically, while India and China account for significant shares of API production.^6-7

For market access professionals, this matters because supply-chain structure is no longer a back-office manufacturing topic. It increasingly shapes product availability, shortage risk, procurement reliability, contract sustainability, and payer confidence. A low-cost generic is only valuable if it remains reliably available.

In line with his American First policy, the Trump Administration’s proposed tariff framework is intended to reduce reliance on imported pharmaceutical products and encourage manufacturers to establish or expand U.S.-based production. The policy rationale is rooted in national security, economic resilience, and concern that excessive dependence on international suppliers may leave the U.S. vulnerable to external disruptions.^3-5

That policy goal is not inherently inconsistent with healthcare access. A more resilient supply chain could, in theory, reduce shortages, improve supply reliability, and strengthen preparedness. However, tariffs are a blunt instrument. They raise the cost of imported products or inputs before domestic capacity necessarily exists at scale. In a high-margin industry, that cost might be absorbed or passed through. In the generic market, the path is far less straightforward.

The eventual impact may also depend on how the policy evolves through trade negotiations. Historically, tariff proposals have often been used as negotiating tools, and the final outcome may differ from the initial announcement. This may be particularly relevant for countries such as India, which plays a central role in the global generic medicines supply chain. Earlier U.S.-India trade discussions referenced potential "negotiated outcomes" for generic pharmaceuticals and related ingredients under the ongoing Section 232 investigation, suggesting that country-specific accommodations or exemptions remain possible. While such measures could lessen the impact for some manufacturers or countries, they do not eliminate the broader questions surrounding manufacturer economics, competition, affordability, and supply continuity that accompany efforts to reshore generic drug production.⁸

This is where the discussion shifts from trade policy to market access. If tariffs increase input costs, manufacturers must decide whether they can absorb the impact, raise prices, shift sourcing, invest in domestic production, exit low-margin products, or prioritize more profitable portfolios. Each choice has consequences for affordability, access, competition, and supply continuity.

At first glance, tariffs may appear to be a relatively straightforward cost issue: if imported generic medicines or their inputs become more expensive, manufacturers could theoretically raise prices to offset the increase. However, the economics of the U.S. generic market make this far more complicated and as mentioned earlier, generics operate on thin margins, which is why the volume is so important.

Generic manufacturers typically compete in multi-source markets where price is the primary differentiator and margins are compressed. AAM data indicate that generic utilization has continued to grow despite the persistent pricing and margin pressures affecting the sector. In market access terms, generics are delivering increasing system-wide value, but manufacturers have limited drug pricing flexibility to absorb new cost pressures such as tariffs.^2,9

The question, therefore, is not whether tariffs increase costs. The more important question is whether manufacturers can recover those costs by changing “price” within the existing U.S. pricing and reimbursement framework. For many generic medicines, that framework includes heavily regulated contracts with the U.S. Government: CMS (Medicaid/Medicare) and HRSA (340B) reference “price” in their contract language. For instance, Medicaid (inflation rebates are linked to Average Manufacturer’s Price (“AMP”), the 340B program where the ceiling price is linked to the Medicaid AMP and Medicaid Rebate, and Medicare where the inflation penalty is tied to Annual AMP. Commercial agreements with payers, hospitals, wholesalers and providers also reference “price” throughout their agreements.^9-10

For example, under the Medicaid Drug Rebate Program, generic manufacturers may owe inflation rebates when Average Manufacturer Price (AMP) increases faster than the relevant inflation benchmark. AMP can increase even when a manufacturer has not deliberately taken a list-price increase, because AMP reflects the average price realized across a changing mix of sales, discounts, contracts, and customers. As a result, input-cost pressure, customer-mix shifts, seasonal purchasing patterns, contracting changes, shortages, or the loss of high-volume discounted customers can all move AMP upward. For a generic manufacturer who receives a 100% tariff, this cost increase may force the manufacturer to have a price increase, which in turn forces the AMP up, triggering an inflation penalty. With the Medicaid rebate cap removed beginning in 2024, the risk is even more significant because total rebates can exceed AMP in certain circumstances resulting in negative sales. This same phenomenon forced multiple branded manufacturers of insulins to lower their price. This creates a market access challenge: even when AMP movement is cost-driven rather than profit-driven, it may still trigger Medicaid inflation rebate liability, further limiting their ability to recover tariff-related costs.⁹ The same is true for the Medicare inflation rebates that came about as a result of the Inflation Reduction Act.

The 340B program further complicates the picture. HRSA’s 340B ceiling price formula is tied to AMP and the Unit Rebate Amount. If a manufacturer raises AMP to offset tariff-driven costs, the action could increase Medicaid rebate exposure and lower the 340B ceiling price.^9,10

This creates significant market access constraints. Generic manufacturers may face higher costs but may not be able to translate those higher costs into improved net revenue. If they do not raise prices, margins compress. If they do raise prices, rebates and 340B mechanics may offset the increase. Either pathway could make some products less attractive to supply, particularly older generics, sterile injectables, difficult-to-manufacture products, or low-volume products with limited profitability.^9,11

Competition is the primary mechanism that makes generics affordable. FDA analyses have consistently shown that prices tend to decline as additional generic competitors enter the market. That principle underpins much of U.S. generic policy, including FDA initiatives such as Generic Drug User Fee Amendments (GDUFA) and the Competitive Generic Therapy program, which are designed to accelerate generic entry and encourage competition in markets with limited alternatives.^12-15

Tariffs could complicate this competitive model by increasing the cost of participating in some markets. Manufacturers with diversified supply chains, stronger balance sheets, existing U.S. infrastructure, or greater ability to invest in domestic capacity may be better positioned to adapt. Smaller or more import-dependent manufacturers may face higher transition costs and less flexibility to absorb short-term margin pressure.^11,16-17

This does not mean that competition will disappear or branded pharmaceutical companies will automatically control the generic market. But it may raise an important strategic question: if reshoring increases the capital intensity of generic manufacturing, could future competition become concentrated among larger, better-capitalized companies? If fewer manufacturers ultimately participate in certain markets, would generic prices continue to experience the same downward pressure that has historically accompanied robust competition?¹⁵

That question is particularly relevant because the generic market already includes large global generic manufacturers, diversified pharmaceutical groups, and some branded companies with generic or off-patent portfolios. These companies may have stronger access to capital, broader manufacturing networks, regulatory infrastructure, and portfolio breadth than smaller or more import-dependent manufacturers. If tariff-driven reshoring increases the cost of market participation, the competitive advantage may shift toward companies that can finance supply-chain restructuring on a scale.

The access risk is not simply higher prices. It is the possibility that fewer manufacturers may be willing or able to enter certain markets in the future. If fewer firms submit Abbreviated New Drug Applications (ANDA), invest in capacity, or remain in low-margin categories, the long-term consequence could be weaker competition, increased vulnerability to shortages, and less durable affordability.^11-13

Reshoring requires more than building manufacturing facilities. It also requires regulatory review, facility registration, supplier qualification, manufacturing site changes, inspections, process validation, and in some cases new or supplemental ANDA activity. The proposed tariff framework gives manufacturers a transition period, but regulatory timelines may become a rate-limiting factor if many companies attempt to modify supply chains simultaneously.^14,18

The FDA has made substantial progress over the past decade through GDUFA, including improved communication with industry and more predictable generic review processes. However, a large-scale reshoring movement could create a different type of workload: not only new ANDAs, but also waves of site transfers, API supplier changes, post-approval supplements, facility inspections, and compliance reviews.^2,14

For market access stakeholders, FDA capacity matters because approval and inspection bottlenecks can delay product availability even when manufacturers are willing to invest. A policy that encourages domestic production but underestimates regulatory throughput could create a timing mismatch: tariffs may arrive before new supply is fully approved and operational.

This may potentially become an access issue. If reshoring lags behind tariff implementation, the healthcare system could experience higher costs and increased supply pressures before benefiting from greater resilience.

If generic drug tariff-related costs cannot be fully absorbed by manufacturers, the economic consequences may extend across multiple access and purchasing channels throughout the pharmaceutical ecosystem, including payers (Commercial, Medicare, Medicaid), 340B covered entities, VA/DoD, hospitals, physician-administered settings, long-term care, home health agencies, pharmacies, wholesalers, and patients. While the magnitude of impact would likely vary by product, channel, and contracting dynamics, stakeholders across the healthcare system could face higher acquisition costs, increased budget pressure, changes in purchasing behavior, or potential disruptions in access and supply. Quantifying those effects would ultimately require product-level analyses that account for reimbursement structures, contracting arrangements, import exposure, and competitive dynamics across different purchasing channels.

Even without a precise dollar estimate, the exposure is potentially enormous because generic medicines account for the majority of prescription volume. For Medicare and Medicaid, even modest price increases across widely used generic medicines could affect public-program spending, depending on how costs flow through reimbursement, rebates, and utilization patterns. For Medicaid specifically, inflation rebate exposure may also influence manufacturer decisions about whether certain products remain commercially attractive.^2,9,11

Hospitals and health systems may face a different set of pressures. Many inpatient and outpatient care pathways rely on mature generic medicines, including sterile injectables and other products used in oncology, anesthesia, critical care, and acute care settings. If tariffs add pressure to already fragile markets, hospitals could face higher procurement costs or greater supply uncertainty, particularly in categories where supplier competition is limited.^13,19

Wholesalers represent another important but less transparent part of the tariff debate. The U.S. distribution system is dominated by three large wholesalers: Cencora, Cardinal Health, and McKesson. Whether higher generic prices improve wholesaler profitability depends on contract structure, fee arrangements, product mix, and customer agreements. It would be overly simplistic to assume that wholesalers automatically benefit from higher prices, but the possibility deserves attention because distribution economics can influence how price changes move through the system.²⁰

The broader market access question is therefore not simply who pays the tariff at the border. The more relevant question is how tariff-driven costs move through regulated drug pricing systems, payer contracts, provider procurement, distribution economics, and patient access pathways.

The proposed generic drug tariff framework raises a legitimate policy objective: strengthening domestic pharmaceutical manufacturing and reducing dependence on global supply chains. A more resilient supply base could improve long-term preparedness and reduce exposure to geopolitical or manufacturing disruptions.

But the generic market is not like the branded pharmaceutical market. Several branded manufacturers were able to secure MFN-related agreements that reportedly provided tariff relief in exchange for drug pricing and investment commitments. Whether a similar framework could emerge for large generic manufacturers remains unclear. Unlike branded manufacturers, generic companies compete primarily on price rather than proprietary products, potentially limiting their leverage in bilateral negotiations. The generic market is built on competition, price erosion, thin margins, and regulated drug pricing obligations. While those dynamics are what make generics affordable, they also limit manufacturers' ability to absorb or pass through tariff-driven cost increases.

The central risk is not only that generic prices may increase. The deeper risk is that tariffs could alter the economics of market participation. Products with limited profitability may become harder to sustain. Smaller or import-dependent manufacturers may face greater barriers. Future generic entrants may become more selective. FDA capacity could become a bottleneck. Hospitals and public programs may experience cost or supply pressure. Wholesaler economics may also shift, though the direction will depend on contract structure.

For policymakers, the challenge is not choosing between affordability and resilience. The challenge is designing a policy environment that supports both. If domestic manufacturing is encouraged without preserving competition, the U.S. may gain supply-chain resilience at the expense of the very affordability foundation generics were designed to provide.

For market access stakeholders, that makes the tariff debate more than a manufacturing story. It is a test of whether the prescription drug component of the U.S. healthcare system can strengthen supply security while preserving the competitive dynamics that keep medicines accessible and affordable. The most important question may not be whether tariffs can bring manufacturing back to the United States, but whether they can do so without weakening the market structure that made generic medicines one of the most successful affordability tools in U.S. healthcare.

Authors

Vimal Sharma

Associate Manager - Market Research, PRMA & HEOR

Matthew Skoronski

Senior Director, PRMA & HEOR

Related Insights

• Blog

  IRA Update: Who "Won" the Initial Price Negotiations?

• Blog

  Initial reactions to the CMS’ release of the MFP

• Blog

  IRA, Inflation Easing and Medicaid Regulations